CIMZIA® (certolizumab pegol) is the only Fc-free PEGylated TNF inhibitor

CIMZIA is a monovalent TNF inhibitor monoclonal antibody fragment. It neutralizes TNF-alpha at low concentrations with a high affinity.1,6,7

Diagram of CIMZIA—PEGylated Fab TNF Inhibitor

Certolizumab pegol does not contain a fragment crystallizable (Fc) region, which is normally present in a complete antibody and, therefore, does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro. It does not induce apoptosis in vitro in human peripheral blood-derived monocytes or lymphocytes, nor does certolizumab pegol induce neutrophil degranulation.1

PEGylation changes the physical and chemical properties of the biomedical molecule6

  • Increases bioavailability of CIMZIA8,9
  • Extends half-life of the antigen binding fragment1,7
  • Increases drug stability and retention time, thereby allowing a reduced dosing frequency6,7

Clinical relevance of in vitro and in vivo data is unknown.